Cortexyme

Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration and beta amyloid production. The target has been validated in a number of animal models and Cortexyme is currently moving a proprietary small molecule towards human clinical testing.